Resumen
Neurobehavioral and cognition problems are highly prevalent in epilepsy, but most research studies to date have not adequately addressed the precise nature of the relationship between these comorbidities and seizures. To address this complex issue and to facilitate collaborative, innovative research in the rising field of neurobehavioral comorbidities and cognition disturbances in new-onset epilepsy, international epilepsy experts met at the 3rd Halifax International Epilepsy Conference & Retreat at White Point, South Shore, Nova Scotia, Canada from September 18 to 20, 2014. This Conference Proceedings provides a summary of the conference proceedings. Specifically, the following topics are discussed: (i) role of comorbidities in epilepsy diagnosis and management, (ii) role of antiepileptic medications in understanding the relationship between epilepsy and neurobehavioral and cognition problems, and (iii) animal data and diagnostic approaches. Evidence to date, though limited, strongly suggests a bidirectional relationship between epilepsy and cognitive and psychiatric comorbidities. In fact, it is likely that seizures and neurobehavioral problems represent different symptoms of a common etiology or network-wide disturbance. As a reflection of this shared network, psychiatric comorbidities and/or cognition problems may actually precede the seizure occurrence and likely get often missed if not screened.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 199-209 |
Número de páginas | 11 |
Publicación | Epilepsy and Behavior |
Volumen | 51 |
DOI | |
Estado | Published - oct. 1 2015 |
Nota bibliográfica
Funding Information:Bernd Pohlmann-Eden received grant funding by Nova Scotia Health Research Foundation. Albert Aldenkamp had no disclosures. Gus Baker had no disclosures. Christian Brandt has received personal compensation from Otsuka, Eisai, Desitin GmbH, Pfizer, and UCB Pharma for serving on scientific advisory boards, for speaking activities, and for congress travel, and financial support for research activities from UCB Pharma and Otsuka. Fernando Cendes had no disclosures. Ronald Coras had no disclosures. Candice E. Crocker had no disclosures. Christoph Helmstaedter had no disclosures. Marilyne Jones-Gotman had no disclosures. Andres M. Kanner had no disclosures. Andrey Mazarati had no disclosures. Marco Mula received consultancy fees from UCB Pharma, Eisai, and Pfizer and supports from Special Products Ltd. and is currently serving as Associate Editor of Epilepsy & Behavior. Mary-Lou Smith had no disclosures. Antonia Omisade had no disclosures. Jose Tellez-Centeno had no disclosures. Bruce P. Hermann had no disclosures.
Publisher Copyright:
© 2015 Elsevier Inc.
ASJC Scopus Subject Areas
- Neurology
- Clinical Neurology
- Behavioral Neuroscience
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Review